US 12,221,428 B2
Use of deuterated empathogens as therapeutic agents
Nicholas V. Cozzi, Slinger, WI (US); and Paul F. Daley, El Sobrante, CA (US)
Assigned to Alexander Shulgin Research Institute, Inc., Lafayette, CA (US)
Filed by Alexander Shulgin Research Institute, Inc., Lafayette, CA (US)
Filed on Jun. 14, 2024, as Appl. No. 18/743,944.
Application 18/743,944 is a division of application No. 18/549,374, previously published as PCT/US2022/041279, filed on Aug. 23, 2022.
Claims priority of provisional application 63/236,224, filed on Aug. 23, 2021.
Claims priority of provisional application 63/236,221, filed on Aug. 23, 2021.
Prior Publication US 2024/0351993 A1, Oct. 24, 2024
Int. Cl. C07D 317/58 (2006.01); A61P 25/00 (2006.01)
CPC C07D 317/58 (2013.01) [A61P 25/00 (2018.01)] 20 Claims
 
1. A method of treating a mental health disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound of any of Formulas (IIIA), (IIIB), (IIIC), (IIIE), (IIIF), (IVA), (IVB), or (IVC):

OG Complex Work Unit Chemistry
wherein each Y is independently protium (H) or deuterium (D), and
wherein at least one Y is deuterium (D) and the remaining Ys are protium (H);
or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof;
provided that the compound is not

OG Complex Work Unit Chemistry
and wherein the mental health disorder is a trauma- or stressor-related disorder, an anxiety disorder, or a depressive disorder.